News stories about Danaher (NYSE:DHR) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Danaher earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the conglomerate an impact score of 46.0885561849687 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Valeant Pharmaceuticals International (VRX) Stock Declined While Balyasny Asset Management Increased Its Stake … – Hill Country Times (hillcountrytimes.com)
- Danaher Simply Blew It Away at This Big Healthcare Conference Tuesday – TheStreet.com (thestreet.com)
- Optimistic Trending Companies: Danaher Corporation (DHR), ZIOPHARM Oncology, Inc. (ZIOP) – Market Movers (financialqz.com)
- DHR Crosses Above Average Analyst Target – Nasdaq (nasdaq.com)
- Danaher Sees RS Rating Rise To 74 (finance.yahoo.com)
A number of research firms have issued reports on DHR. Robert W. Baird reissued a “buy” rating on shares of Danaher in a research report on Friday. Zacks Investment Research lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Credit Suisse Group reaffirmed a “hold” rating and set a $99.00 price objective on shares of Danaher in a research note on Tuesday, December 19th. Royal Bank of Canada reaffirmed a “hold” rating and set a $96.00 price objective on shares of Danaher in a research note on Thursday, January 4th. Finally, Evercore ISI started coverage on shares of Danaher in a research note on Wednesday, January 3rd. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $94.91.
Shares of Danaher (NYSE:DHR) opened at $99.39 on Friday. The stock has a market cap of $69,136.18, a PE ratio of 25.55, a P/E/G ratio of 2.15 and a beta of 1.02. Danaher has a fifty-two week low of $78.97 and a fifty-two week high of $99.66. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.05. The firm had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. Danaher’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 EPS. equities analysts predict that Danaher will post 3.99 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.14 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. Danaher’s dividend payout ratio (DPR) is presently 16.52%.
In other news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Daniel L. Comas sold 88,184 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $91.02, for a total value of $8,026,507.68. Following the transaction, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at $20,735,812.32. The disclosure for this sale can be found here. Insiders have sold 273,810 shares of company stock worth $25,218,813 over the last quarter. Insiders own 12.20% of the company’s stock.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.